Inhibikase Therapeutics is a biopharmaceutical company that specializes in developing disruptive therapies for neurodegenerative diseases and fatal brain infections. They focus on intervening in the early stages of neurodegeneration to reverse its effects and target the source of neurological infections. Their drug development programs aim to halt and reverse the progression of neurodegenerative diseases inside and outside of the brain.

Inhibikase's proprietary RAMP™ drug innovation engine allows them to design and develop new chemical entities with improved potency, penetration into the brain, and safety profiles. They also utilize a prodrug technology platform to enhance drug delivery and control side effects. Inhibikase is committed to elucidating disease mechanisms through collaborations to properly target neurological diseases.

They offer therapeutic solutions for Parkinson's Disease, Chronic Myeloid Leukemia (CML), and Progressive Multifocal Leukoencephalopathy (PML). With their innovative treatments, Inhibikase aims to make a significant impact on the lives of patients suffering from these debilitating conditions